Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

SIRT1-independent mechanisms of the putative sirtuin enzyme activators SRT1720 and SRT2183.

Huber JL, McBurney MW, Distefano PS, McDonagh T.

Future Med Chem. 2010 Dec;2(12):1751-9. doi: 10.4155/fmc.10.257.

PMID:
21428798
2.

A patent review of sirtuin activators: an update.

Villalba JM, de Cabo R, Alcain FJ.

Expert Opin Ther Pat. 2012 Apr;22(4):355-67. doi: 10.1517/13543776.2012.669374. Epub 2012 Mar 9. Review.

PMID:
22475539
3.

AROuSing SIRT1: identification of a novel endogenous SIRT1 activator.

Verdin E.

Mol Cell. 2007 Nov 9;28(3):354-6. Review.

4.

Sirtuin 1 (SIRT1): the misunderstood HDAC.

Stünkel W, Campbell RM.

J Biomol Screen. 2011 Dec;16(10):1153-69. doi: 10.1177/1087057111422103. Epub 2011 Nov 15. Review.

PMID:
22086720
5.

Sirtuin activators and inhibitors.

Villalba JM, Alcaín FJ.

Biofactors. 2012 Sep-Oct;38(5):349-59. doi: 10.1002/biof.1032. Epub 2012 Jun 25. Review.

6.

Biochemical effects of SIRT1 activators.

Baur JA.

Biochim Biophys Acta. 2010 Aug;1804(8):1626-34. doi: 10.1016/j.bbapap.2009.10.025. Epub 2009 Nov 6. Review.

7.

Sirtuin activators.

Alcaín FJ, Villalba JM.

Expert Opin Ther Pat. 2009 Apr;19(4):403-14. doi: 10.1517/13543770902762893. Review.

PMID:
19441923
8.

Sirtuin modulators: an updated patent review (2012 - 2014).

Mellini P, Valente S, Mai A.

Expert Opin Ther Pat. 2015 Jan;25(1):5-15. doi: 10.1517/13543776.2014.982532. Epub 2014 Nov 29. Review.

PMID:
25435179
9.

Sirtuins and p53.

van Leeuwen I, Lain S.

Adv Cancer Res. 2009;102:171-95. doi: 10.1016/S0065-230X(09)02005-3. Review.

PMID:
19595309
10.

Anticancer agents targeted to sirtuins.

Kozako T, Suzuki T, Yoshimitsu M, Arima N, Honda S, Soeda S.

Molecules. 2014 Dec 4;19(12):20295-313. doi: 10.3390/molecules191220295. Review.

11.

Are sirtuins viable targets for improving healthspan and lifespan?

Baur JA, Ungvari Z, Minor RK, Le Couteur DG, de Cabo R.

Nat Rev Drug Discov. 2012 Jun 1;11(6):443-61. doi: 10.1038/nrd3738. Review.

12.

How does SIRT1 affect metabolism, senescence and cancer?

Brooks CL, Gu W.

Nat Rev Cancer. 2009 Feb;9(2):123-8. doi: 10.1038/nrc2562. Epub 2008 Dec 29. Review.

13.

Sirtuins: novel targets for metabolic disease.

Elliott PJ, Jirousek M.

Curr Opin Investig Drugs. 2008 Apr;9(4):371-8. Review.

PMID:
18393104
14.

Catalysis and mechanistic insights into sirtuin activation.

Dittenhafer-Reed KE, Feldman JL, Denu JM.

Chembiochem. 2011 Jan 24;12(2):281-9. doi: 10.1002/cbic.201000434. Epub 2010 Nov 9. Review.

15.

Sirtuin activators: designing molecules to extend life span.

Camins A, Sureda FX, Junyent F, Verdaguer E, Folch J, Pelegri C, Vilaplana J, Beas-Zarate C, Pallàs M.

Biochim Biophys Acta. 2010 Oct-Dec;1799(10-12):740-9. doi: 10.1016/j.bbagrm.2010.06.005. Epub 2010 Jun 23. Review.

PMID:
20601277
16.

Slowing ageing by design: the rise of NAD+ and sirtuin-activating compounds.

Bonkowski MS, Sinclair DA.

Nat Rev Mol Cell Biol. 2016 Nov;17(11):679-690. doi: 10.1038/nrm.2016.93. Epub 2016 Aug 24. Review.

17.

How much successful are the medicinal chemists in modulation of SIRT1: A critical review.

Kumar A, Chauhan S.

Eur J Med Chem. 2016 Aug 25;119:45-69. doi: 10.1016/j.ejmech.2016.04.063. Epub 2016 Apr 27. Review.

PMID:
27153347
18.

Role of Sirtuins in Regulating Pathophysiology of the Heart.

Bindu S, Pillai VB, Gupta MP.

Trends Endocrinol Metab. 2016 Aug;27(8):563-573. doi: 10.1016/j.tem.2016.04.015. Epub 2016 May 19. Review.

PMID:
27210897

Supplemental Content

Support Center